These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 23569309)

  • 1. Phase III, multicenter, randomized trial of maintenance chemotherapy versus observation in patients with metastatic breast cancer after achieving disease control with six cycles of gemcitabine plus paclitaxel as first-line chemotherapy: KCSG-BR07-02.
    Park YH; Jung KH; Im SA; Sohn JH; Ro J; Ahn JH; Kim SB; Nam BH; Oh DY; Han SW; Lee S; Park IH; Lee KS; Kim JH; Kang SY; Lee MH; Park HS; Ahn JS; Im YH
    J Clin Oncol; 2013 May; 31(14):1732-9. PubMed ID: 23569309
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quality of life (QoL) in metastatic breast cancer patients with maintenance paclitaxel plus gemcitabine (PG) chemotherapy: results from phase III, multicenter, randomized trial of maintenance chemotherapy versus observation (KCSG-BR07-02).
    Park YH; Jung KH; Im SA; Sohn JH; Ro J; Ahn JH; Kim SB; Nam BH; Oh DY; Han SW; Lee S; Park IH; Lee KS; Kim JH; Kang SY; Lee MH; Park HS; Woo SY; Jung SH; Ahn JS; ; Im YH
    Breast Cancer Res Treat; 2015 Jul; 152(1):77-85. PubMed ID: 26033708
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II, multicentre, randomised trial of eribulin plus gemcitabine versus paclitaxel plus gemcitabine as first-line chemotherapy in patients with HER2-negative metastatic breast cancer.
    Park YH; Im SA; Kim SB; Sohn JH; Lee KS; Chae YS; Lee KH; Kim JH; Im YH; Kim JY; Kim TY; Lee KH; Ahn JH; Kim GM; Park IH; Lee SJ; Han HS; Kim SH; Jung KH;
    Eur J Cancer; 2017 Nov; 86():385-393. PubMed ID: 29100193
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quality of life outcomes including neuropathy-associated scale from a phase II, multicenter, randomized trial of eribulin plus gemcitabine versus paclitaxel plus gemcitabine as first-line chemotherapy for HER2-negative metastatic breast cancer: Korean Cancer Study Group Trial (KCSG BR13-11).
    Kim JY; Park S; Im SA; Kim SB; Sohn J; Lee KS; Chae YS; Lee KH; Kim JH; Im YH; Kim TY; Lee KH; Ahn JH; Kim GM; Park IH; Lee SJ; Han HS; Kim SH; Jung KH; Park YH;
    Cancer Commun (Lond); 2019 May; 39(1):29. PubMed ID: 31138332
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination versus sequential paclitaxel plus gemcitabine as first-line chemotherapy for women with metastatic breast cancer: a prospective randomized phase II study.
    Shao B; Song G; Li H; Dil L; Jiang H; Liang X; Yan Y; Zhang R; Ran R; Wang J; Liu X; You M
    J BUON; 2018; 23(6):1583-1590. PubMed ID: 30610781
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Caveolin-1 expression predicts efficacy of weekly nab-paclitaxel plus gemcitabine for metastatic breast cancer in the phase II clinical trial.
    Zhao Y; Lv F; Chen S; Wang Z; Zhang J; Zhang S; Cao J; Wang L; Cao E; Wang B; Hu X
    BMC Cancer; 2018 Oct; 18(1):1019. PubMed ID: 30348118
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cisplatin plus gemcitabine versus paclitaxel plus gemcitabine as first-line therapy for metastatic triple-negative breast cancer (CBCSG006): a randomised, open-label, multicentre, phase 3 trial.
    Hu XC; Zhang J; Xu BH; Cai L; Ragaz J; Wang ZH; Wang BY; Teng YE; Tong ZS; Pan YY; Yin YM; Wu CP; Jiang ZF; Wang XJ; Lou GY; Liu DG; Feng JF; Luo JF; Sun K; Gu YJ; Wu J; Shao ZM
    Lancet Oncol; 2015 Apr; 16(4):436-46. PubMed ID: 25795409
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genetic polymorphisms of SLC28A3, SLC29A1 and RRM1 predict clinical outcome in patients with metastatic breast cancer receiving gemcitabine plus paclitaxel chemotherapy.
    Lee SY; Im SA; Park YH; Woo SY; Kim S; Choi MK; Chang W; Ahn JS; Im YH
    Eur J Cancer; 2014 Mar; 50(4):698-705. PubMed ID: 24361227
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Paclitaxel and gemcitabine as salvage treatment in metastatic breast cancer.
    Murad AM
    Oncology (Williston Park); 2003 Dec; 17(12 Suppl 14):26-32. PubMed ID: 14768402
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized phase II study of paclitaxel and bevacizumab with and without gemcitabine as first-line treatment for metastatic breast cancer.
    Brufsky A; Hoelzer K; Beck T; Whorf R; Keaton M; Nadella P; Krill-Jackson E; Kroener J; Middleman E; Frontiera M; Paul D; Panella T; Bromund J; Zhao L; Orlando M; Tai F; Marciniak MD; Obasaju C; Hainsworth J
    Clin Breast Cancer; 2011 Aug; 11(4):211-20. PubMed ID: 21723792
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biweekly gemcitabine-paclitaxel, gemcitabine-carboplatin, or gemcitabine-cisplatin as first-line treatment in metastatic breast cancer after anthracycline failure: a phase II randomized selection trial.
    Xu B; Jiang Z; Kim SB; Yu S; Feng J; Malzyner A; Del Giglio A; Chung HC; Shen LJ; Pen DL
    Breast Cancer; 2011 Jul; 18(3):203-12. PubMed ID: 21465229
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Switch maintenance chemotherapy versus observation after carboplatin and weekly paclitaxel doublet chemotherapy in elderly patients with advanced non-small cell lung cancer: IFCT-1201 MODEL trial.
    Quoix E; Audigier-Valette C; Lavolé A; Molinier O; Westeel V; Barlesi F; Le Treut J; Pichon E; Dauba J; Otto J; Moreau L; Madelaine J; Dumont P; Margery J; Debieuvre D; Renault PA; Pujol JL; Langlais A; Morin F; Moro-Sibilot D; Souquet PJ
    Eur J Cancer; 2020 Oct; 138():193-201. PubMed ID: 32898792
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II/III weekly nab-paclitaxel plus gemcitabine or carboplatin versus gemcitabine/carboplatin as first-line treatment of patients with metastatic triple-negative breast cancer (the tnAcity study): study protocol for a randomized controlled trial.
    Yardley DA; Brufsky A; Coleman RE; Conte PF; Cortes J; Glück S; Nabholtz JM; O'Shaughnessy J; Beck RM; Ko A; Renschler MF; Barton D; Harbeck N
    Trials; 2015 Dec; 16():575. PubMed ID: 26673577
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Final Results of the Randomized Phase II NorCap-CA223 Trial Comparing First-Line All-Oral Versus Taxane-Based Chemotherapy for HER2-Negative Metastatic Breast Cancer.
    Cinieri S; Chan A; Altundag K; Vandebroek A; Tubiana-Mathieu N; Barnadas A; Dodyk P; Lazzarelli S; Botha M; Rauch D; Villanova G; Coskun U
    Clin Breast Cancer; 2017 Apr; 17(2):91-99.e1. PubMed ID: 27756583
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Exploratory biomarker analysis from a phase II clinical trial of eribulin plus gemcitabine versus paclitaxel plus gemcitabine for HER2-negative metastatic breast cancer patients (KCSG BR13-11).
    Kim JY; Lee E; Park K; Im SA; Sohn J; Lee KS; Chae YS; Kim JH; Kim TY; Jung KH; Park YH;
    Breast Cancer Res Treat; 2019 Nov; 178(2):367-377. PubMed ID: 31407230
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II trial of preoperative paclitaxel, gemcitabine, and trastuzumab combination therapy in HER2 positive stage II/III breast cancer: the Korean Cancer Study Group BR 07-01.
    Im SA; Lee KS; Ro J; Lee ES; Kwon Y; Ahn JH; Ahn JS; Kim JH; Kang HS; Shin KH; Noh DY; Park IA; Kim SB; Im YH; Ha SW
    Breast Cancer Res Treat; 2012 Apr; 132(2):589-600. PubMed ID: 22094934
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Final results of a phase II study of nab-paclitaxel, bevacizumab, and gemcitabine as first-line therapy for patients with HER2-negative metastatic breast cancer.
    Lobo C; Lopes G; Baez O; Castrellon A; Ferrell A; Higgins C; Hurley E; Hurley J; Reis I; Richman S; Seo P; Silva O; Slingerland J; Tukia K; Welsh C; Glück S
    Breast Cancer Res Treat; 2010 Sep; 123(2):427-35. PubMed ID: 20585851
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II trial of gemcitabine/doxorubicin/paclitaxel administered every other week in patients with metastatic breast cancer.
    Sánchez-Rovira P; Jaén A; González E; Porras I; Dueñas MR; Medina B; Mohedano N; Fernández M; Martos M; Lozano A
    Clin Breast Cancer; 2000 Oct; 1(3):226-32. PubMed ID: 11899647
    [TBL] [Abstract][Full Text] [Related]  

  • 19. First-line therapy with gemcitabine and paclitaxel in locally, recurrent or metastatic breast cancer: a phase II study.
    Allouache D; Gawande SR; Tubiana-Hulin M; Tubiana-Mathieu N; Piperno-Neumann S; Mefti F; Bozec L; Genot JY
    BMC Cancer; 2005 Nov; 5():151. PubMed ID: 16316459
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nab-Paclitaxel and Gemcitabine as First-line Treatment of Advanced or Metastatic Cholangiocarcinoma: A Phase 2 Clinical Trial.
    Sahai V; Catalano PJ; Zalupski MM; Lubner SJ; Menge MR; Nimeiri HS; Munshi HG; Benson AB; O'Dwyer PJ
    JAMA Oncol; 2018 Dec; 4(12):1707-1712. PubMed ID: 30178032
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.